If Dry Eye Disease symptoms persist

IS IT TiiME TO CONSIDER Xiidra®

CONSIDER Xiidra® AS YOUR FIRST CHOICE FOR PATIENTS WITH SYMPTOMATIC DRY EYE DISEASE?

XIIDRA® is indicated for the treatment of the signs and symptoms of Dry Eye Disease.

Canadian Market Experiience Since 2017*

XIIDRA® is the first and only molecule in its class.†

XIIDRA® (lifitegrast) is a lymphocyte-function associated antigen-1 (LFA-1) antagonist.

Click here for additional safety information and for a link to the Product Monograph discussing:

Contraindications in patients with hypersensitivity to this drug or to any ingredients in the formulation or component of the container.

Relevant warnings and precautions regarding driving and operating machinery immediately following the use of XIIDRA®, regarding the use of XIIDRA® by pregnant and breastfeeding women, and children under 17 years of age, and regarding hypersensitivity reactions following the use of XIIDRA®.

Conditions of clinical use, adverse reactions, drug interactions, and dosing and administration.

The Product Monograph is also available by calling 1-888-459-5000.

* Clinical significance has not been established.

† Comparative clinical significance is unknown.

This site is intended for Health Care Professionals only. Visit the Patient Website. Password (XIIDRA® DIN): 02471027